During recent years several anti-Plasmodium vaccines have been proposed to combat malaria (i.e, RTS,S and R21) . After numerous investigations , a successful CSP-based subunit vaccine (RTS,S) inducing < 40% protection, was first developed. The RTS,S vaccine included 19 NANP repeats and the C-terminal region III-TSR fused to an hepatitis antigen to increase its immunogenicity. Most recently, a modified R21/Matrix-M malaria vaccine has improved protection levels to < 80% . RTS,S and R21 are now recommended by the World Health Organization (WHO) . Double-blind, randomized, phase 3trial of the R21/Matrix-M malaria vaccine across four African countries with differing malaria transmission intensities, was well tolerated and offered ~ 75 % protection efficacy against children clinical malaria .